GlassScriptPhysician profile
Unnati Sampat
NPI 1699976415
$6,678.95
in general payments reported to CMS, 2019-2025
38 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $473 · 2021: $1,272 · 2022: $799 · 2023: $816 · 2024: $1,438 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,326 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,325.86 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,302.91 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $659.88 | 2020-2025 | Avycaz |
| Bayer Healthcare Pharmaceuticals INC. | $626.51 | 2021-2025 | |
| Novo Nordisk INC | $549.76 | 2019-2025 | Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $380.06 | 2019-2022 | |
| Lilly USA, LLC | $333.07 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $274.76 | 2019-2024 | |
| Radius Health, INC. | $258.61 | 2023-2024 | Tymlos |
| Amgen INC. | $242.98 | 2019-2025 | Evenity, Repatha, Prolia |
| Glaxosmithkline, LLC. | $207.53 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $179.78 | 2019-2023 | Verquvo, Belsomra, Januvia |
| Ironwood Pharmaceuticals, INC | $175.44 | 2020-2024 | Linzess |
| Corcept Therapeutics | $158.24 | 2021-2025 | Korlym |
| Astellas Pharma US INC | $155.75 | 2019-2025 | |
| Philips North America LLC | $148.03 | 2021-2025 | (5044) Mcot, (Ck7) Extended Holter, Extended Holter |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Unnati Sampat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.